Vascular Biogenics Ltd expected to post a loss of 11 cents a share - Earnings Preview

Notable Labs

12/11/2021 16:32

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected to show
a fall in quarterly revenue when it reports  results on November
15. 
* The Modiin, Israel-based company is expected to report  a
22.3% decrease in revenue to $150 thousand from $193 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Vascular Biogenics Ltd
is for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5.25​, about 52% above​ its last closing price
of $2.52. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.11       -0.11      -0.12     Missed  -11.6
 Mar. 31 2021  -0.13       -0.13      -0.12     Beat    7.7
 Dec. 31 2020              -0.14      -0.15     Missed  -7.1​
 Sep. 30 2020  -0.14       -0.13      -0.12     Beat    10.2
 ​​Jun.        -0.14       -0.14      -0.14     Met     -1.4
 30 2020                                                
 Mar. 31 2020  -0.17       -0.17      -0.15     Beat    9.4​
 Dec. 31 2019  -0.13       -0.13      -0.16     Missed  -19.4
 Sep. 30 2019  -0.16       -0.14      -0.14     Met     1.8
 This summary was machine generated November 12 at 16:32 GMT. 
All figures in US dollars  unless otherwise stated